MedTrace Logo

A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh

NCT04434144 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2020-06-16

No results posted yet for this study

Summary

COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Like other countries of the world, Bangladesh is also struggling in the case of treatment of this disease. Besides antiviral drugs other existing drugs like Hydroxychloroquine, Chloroquine, and recently Ivermectin has been used for the treatment of mild to moderate cases of COVID19 disease. Till now Hydroxychloroquine has shown a good effect. Recently anti-parasitic drug Ivermectin was found highly effective in an in-vitro study against SARS-CoV-2. This study is aimed to evaluate the efficacy of Ivermectin and Hydroxychloroquine as a combination therapy with antibiotics (Doxycyclin and Azithromycin) and compare the recovery period of these two drugs applied as core monotherapy.

Conditions

  • Ivermectin
  • Hydroxychloroquine
  • COVID19

Interventions

DRUG

Ivermectin + Doxycycline

SARS-CoV-2 infection was confirmed by RT PCR in every case. For group A, Ivermectin 200mcg/kg single dose and Doxycycline 100mg BID for 10 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 3rd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.

DRUG

Hydroxychloroquine + Azithromycin

SARS-CoV-2 infection was confirmed by RT PCR in every case. For group B, Hydroxychloroquine 400mg first day then 200mg BID + Azithromycin 500mg BID for 5 days were given. For group B, Hydroxychloroquine 200mg BID for 10 days and Azithromycin 500mg single daily dose for 5days was given. Before advising the contraindications and possible adverse effect and drug interactions were kept in consideration. Incase of asymptomatic patients, repeat sample collection (nasopharyngeal and throat swab) for PCR was done on 5th day. For the symptomatic patients, this duration was on the 2nd nonsymptomatic day from the first day of drug intake. In the case of positive PCR, the test was repeated after 2days and onward.

Sponsors & Collaborators

  • Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar

    lead OTHER_GOV

Principal Investigators

  • Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD · First Affiliated Hospital Xi'an Jiaotong University

  • Mohammad Shahbaz, MBBS, MCPS · Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar

Eligibility

Min Age
16 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-02
Primary Completion
2020-06-05
Completion
2020-06-05
FDA Drug
Yes

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04434144 on ClinicalTrials.gov